Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jorge Saucedo to Platelet Glycoprotein GPIIb-IIIa Complex

This is a "connection" page, showing publications Jorge Saucedo has written about Platelet Glycoprotein GPIIb-IIIa Complex.

 
Connection Strength
  
 
 
1.096
  
  1. Hanna EB, Rao SV, Manoukian SV, Saucedo JF. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. JACC Cardiovasc Interv. 2010 Dec; 3(12):1209-19.
    View in: PubMed
    Score: 0.341
  2. Saucedo JF, Garza L, Wolford DC, Cook SL, Ramanathan KB, Matin Z, McGrew FA, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am J Cardiol. 2004 May 15; 93(10):1279-82.
    View in: PubMed
    Score: 0.217
  3. Roe MT, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, van't Hof AW, Montalescot G, James SK, Saucedo J, Ohman EM, Pollack CV, Hochman JS, Armstrong PW, Giugliano RP, Harrington RA, Van de Werf F, Califf RM, Newby LK. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):205-13.
    View in: PubMed
    Score: 0.093
  4. Cohen M, Hoekstra J, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Pollack CV, Saucedo JF. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. J Interv Cardiol. 2008 Aug; 21(4):283-99.
    View in: PubMed
    Score: 0.073
  5. Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Curr Opin Cardiol. 2008 Jul; 23(4):302-8.
    View in: PubMed
    Score: 0.072
  6. Saucedo JF, Aude W, Pacheco R, Thorn B, Matin Z, Husain K, Garza L. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). Am J Cardiol. 2005 Jun 15; 95(12):1453-6.
    View in: PubMed
    Score: 0.058
  7. Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. J Thromb Thrombolysis. 2004 Oct; 18(2):67-74.
    View in: PubMed
    Score: 0.056
  8. Saucedo JF, Hennebry TA. Use of the early invasive approach in the management of acute coronary syndromes. Curr Cardiol Rep. 2004 Jul; 6(4):287-91.
    View in: PubMed
    Score: 0.055
  9. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004 Feb 15; 93(4):453-5.
    View in: PubMed
    Score: 0.053
  10. Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo JF, Talley JD, Lui H, Kitt MM, Califf RM, Tcheng JT. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am J Cardiol. 2002 Sep 15; 90(6):585-90.
    View in: PubMed
    Score: 0.048
  11. Hoekstra J, Cohen M, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Saucedo JF, Pollack CV. Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. Am J Emerg Med. 2009 Jul; 27(6):720-8.
    View in: PubMed
    Score: 0.019
  12. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001 May 29; 103(21):2572-8.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.